Mid-Study Peek at Merck's Once-A-Month HIV Preventative Shows Promise

Merck & Co. announced data from its Phase IIa trial of islatravir for pre-exposure prophylaxis (PrEP) of HIV-1 infection in adults who are at low risk of contracting HIV. The drug is a nucleoside reverse transcriptase translocation inhibitor, with the results presented at the virtual 11th International AIDS Society Conference on HIV Science (IAS 2021).